Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)
Lay Description
This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters
Category
- Child Health
- IRB Number
- 20180118HU
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Mary Woolsey
210-567-8049
woolseym@uthscsa.edu
Principal Investigator
Peter Fox